Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2013	Country Report: Indonesia Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's healthcare system has turned "improving quality" into the top priority of the government of Indonesia.
Pharmaceutical Executive May 1, 2012	Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive March 1, 2013	Country Report: China China's pharmaceutical industry is making record gains. Four years ago, China was the world's fifth largest market. Now, it has bypassed France and Germany to become the third largest.
Pharmaceutical Executive August 1, 2014	Country Report: Chile 2014 kicks off a defining period for healthcare in Chile as a new national drug law is implemented
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Pharmaceutical Executive July 1, 2009	The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.
Pharmaceutical Executive August 1, 2012	Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years.
Pharmaceutical Executive June 1, 2011	Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China.
Pharmaceutical Executive October 1, 2006 Ray Hill	China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge.
Pharmaceutical Executive September 1, 2012 Thomas Baker	The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support.
Pharmaceutical Executive May 1, 2014 Nadeem Rehmat	Gravity Shift: Timely Lessons For Big Pharma MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive October 1, 2006	Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs.
Pharmaceutical Executive February 1, 2011 William Looney	Tracking the US Market: A Statistical Self-Portrait What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light
Knowledge@Wharton	Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new study comparing average prices for pharmaceuticals in nine countries -- the US, Canada, Chile, France, Germany, Italy, Japan, Mexico and the UK -- shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the US.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive August 1, 2005 Lena Chow	Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Financial Planning April 1, 2006 Donald Jay Korn	Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds.
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
Pharmaceutical Executive February 1, 2009 Jill Wechsler	Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
Pharmaceutical Executive November 1, 2006	Alternative Media: Time to Change the Channel Upgraded hospital television and Internet systems equal new marketing opportunities.
Pharmaceutical Executive November 1, 2008 Sarah Houlton	Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Pharmaceutical Executive June 9, 2014 Genenz et al.	Surviving the Price Wars in Emerging Markets: Three Myths and Three Lessons How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann	Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact.
Pharmaceutical Executive May 1, 2006 Sarah Houlton	Global Report: A Hope and a Payer If current trends continue, the United Kingdom will spend 12.7 percent of its GDP on healthcare by 2050. Maybe that means it's time to reform the National Health Service's notoriously complex drug payment scheme.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
Nursing Management June 2011 LaRocco & Pinchera	The emerging trend of medical tourism Although it's difficult to find accurate data, there's general agreement that the number of Americans seeking medical care abroad is growing.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
HBS Working Knowledge April 5, 2004 Jonathan Byrnes	Fixing the Healthcare Supply Chain The paradox of healthcare supply chains is that they are the home of some of the best and worst practices in supply chain management. With limited hospital budgets, supply chain inefficiencies consume resources that could be used to bring important therapies into more widespread availability.
The Motley Fool June 26, 2006 Stephen D. Simpson	Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note.
Pharmaceutical Executive January 1, 2013	Country Report: Singapore Most executives across the pharmaceutical industry agree; Singapore does not represent any question marks in the future. Furthermore, Singapore's location is ideal for reaching markets east, west, north and south, which form the powerhouse that is Asia-Pacific.
Chemistry World July 16, 2012 Andrew Turley	Drug spending to hit $1.2tn in 2016 Global expenditure on medicines will top $1.2 trillion in 2016, up from $960 billion in 2011, according to a report from the IMS Institute for Healthcare Informatics.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
Knowledge@Wharton August 27, 2003	Code Blue: Combating Rising Healthcare Costs Calls for Strong Medicine It's been said many times over that the U.S. healthcare industry is a sick patient in search of a cure. The metaphor is a grim reflection of how the country is coping with an aging population, rising costs and an inefficient healthcare delivery system.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
Pharmaceutical Executive August 1, 2006 Patrick Clinton	From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible.
Pharmaceutical Executive January 1, 2007 Walter Armstrong	Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
The Motley Fool March 14, 2008 Stephen Albainy-Jenei	The War on (the Cost of) Drugs Pharmaceutical companies could be hurt by countries disregarding drug patents.